Eterna Therapeutics
ERNA
#9525
Rank
A$46.43 M
Marketcap
$0.90
Share price
10.38%
Change (1 day)
-41.31%
Change (1 year)

P/E ratio for Eterna Therapeutics (ERNA)

P/E ratio as of November 2024 (TTM): -0.0944

According to Eterna Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0943617. At the end of 2021 the company had a P/E ratio of -1.50.

P/E ratio history for Eterna Therapeutics from 2021 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2021-1.50

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
6.44-6,928.36%๐Ÿ‡บ๐Ÿ‡ธ USA
-11.8 12,429.98%๐Ÿ‡บ๐Ÿ‡ธ USA
12.1-12,899.79%๐Ÿ‡บ๐Ÿ‡ธ USA
15.1-16,088.37%๐Ÿ‡ซ๐Ÿ‡ท France
45.3-48,058.86%๐Ÿ‡บ๐Ÿ‡ธ USA
N/AN/A๐Ÿ‡ฆ๐Ÿ‡บ Australia
-8.54 8,950.28%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.